Clinical Efficacy of the Neutralizing Antibody Therapy Sotrovimab in Patients with SARS-CoV-2 Omicron BA.1 and BA.2 Subvariant Infections
Miyashita et al., Viruses, doi:10.3390/v15061300
https://c19early.org/miyashita2.html